SYMPOSIA

Poster Presentations
80 mg/day (dosed 40 mg BID) for a minimum of 7 days. At Visit 5, or any visit thereafter, the dose could be increased to the maximum of
100 mg/day (dosed 50 mg BID) depending upon continued ADHD symptoms. One unscheduled dose change was allowed if needed for
tolerability or safety. The Conners’ Adult ADHD Rating Scale- Investigator Rated, Screening Version Total ADHD Symptoms score (CAARS
– Inv:SV) with adult ADHD prompts, assessed core ADHD symptoms and was the primary efficacy measure. The adult ADHD Quality of
Life-29 (AAQOL-29) scale evaluated functional outcomes in various life domains. Other assessments included Clinical Global Impression-
ADHD-Severity (CGI-ADHD-S), CAARS Self Report (CAARS-S:SV), Patient Global Impression-Improvement (PGI-I), Behavior Rating Inventory
of Executive Function-Adult Version Self Report (BRIEF-A), and measures for depression, anxiety, sleepiness, driving behaviors, social
adaptation, and substance use. Reported means are least-squares means from last-observation-carried-forward ANCOVA models. A
mixed-model repeated measures visit-wise analysis was also conducted.
Results: Significant improvement (mean±SE) after ATX treatment was demonstrated on CAARS-Inv:SV (ATX [-13.6±0.8] vs. PBO [-9.3±0.8],
p